CClinicalTrials.gg
RecruitingNCT07844317Updated Sep 28, 2026

Pivotal Trial for an Automated AI-based System for Detection of Diabetic Retinopathy

An observational study in Diabetic Retinopathy (DR), sponsored by Digital Diagnostics, Inc.. Recruiting at 1 site in United States. Open to participants aged 22 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Digital Diagnostics, Inc. · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
800
Ages
22 Years and older
Sex
All
01

Study summary

Assessment of an autonomous AI system for diabetic retinopathy detection in adults with diabetes using retinal imaging.

02

Conditions studied

  • Diabetic Retinopathy (DR)

Browse trials for

Keywords

  • AI-enabled
  • Diabetic Retinopathy
03

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Diabetic adult population with no previous diagnosis of DR

Inclusion criteria

  • 22 years of age or older
  • Diagnosis of DM
  • Ability to understand and willing to sign a written ICF

Exclusion criteria

Exclusion Criteria:

Participants may be excluded if they have significant ocular conditions or prior ocular treatments that could interfere with retinal imaging or study assessments; are currently participating in another interventional ophthalmic clinical trial; have medical conditions that may affect study participation or data interpretation; are pregnant; or have contraindications to study-related imaging procedures.

04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
800 participants (estimated)
Patient registry
No

Groups and cohorts

  • Single arm, non-randomized cohort

    Adult, 22 years or older with a diagnosis of diabetes

    Device: SaMD intended for the detection of diabetic retinopathy in adults with diabetes. · Device: An AI/ML-based Software as a Medical Device (SaMD) for the automated detection of diabetic retinopathy in adults with diabetes.

Interventions

  • DeviceSaMD intended for the detection of diabetic retinopathy in adults with diabetes.

    No significant difference to other SaMDs for the detection of DR that are commercialized.

  • DeviceAn AI/ML-based Software as a Medical Device (SaMD) for the automated detection of diabetic retinopathy in adults with diabetes.

    SaMD to detect diabetic retinopathy

    Also known as: AI/ML, SaMD

05

What researchers measure

Primary outcomes

  1. Evaluation of the safety and efficacy of an AI-based SaMD with a fundus camera for the detection of Diabetic Retinopathy

    Time frame: 1-year

06

Study locations

1 of 1 sites recruiting
  • Rovia Site Network
    Jacksonville, Florida 32216, United States
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07844317
Lead sponsor
Digital Diagnostics, Inc.
Responsible party
Sponsor
First posted
Sep 28, 2026
Start date
Aug 24, 2026
Primary completion
May 30, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Sep 28, 2026

Study contacts

Audrey Singh Singh
Contact
singh@digitaldiagnostics.com
7633702127

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion